Objective To analyze the occurrence features of adverse events following immunization ( AEFI ) surveillance of absorbed diphtheria, tetanus and acellular pertusis combined vaccine ( DTaP ) in Fengtai District of Beijing and to evaluate the immunization safety of DTaP and the running condition of AEFI surveillance system. Methods AEFI data of Fengtai District of Beijing from 2008 to 2011 were collected through AEFI Information System and China immunization information system and epide-miological analysis was conducted by using descriptive methods. Results Totally 61 DTaP AEFI cases were reported from 2008 to 2011 in Fengtai District of Beijing by the surveillance system. The report incidence rate of AEFI was 13. 88/100 000 doses and most of AEFI were reported during May to August. The DTaP AEFI incidence of 2008 ,2009,2010 and 2011 showed statistically significant differences (x2 = 17. 312, P =0.001 ),and the incidence in 2011 was much higher than 2009 (x2 = 11.018,P = 0. 001 ). The DTaP AEFI incidence of different dose showed statistically significant difference (x2 =95. 586,P =0. 000 ). The 4th dose incidence was significantly higher than the first,second and thrid dose (X2 =38. 604,39. 805 ,35. 105 ,P =0. 000 ). Among all AEFI reported,50 cases was common minor reaction (11. 38/100 000 doses ) with fever ( ≥38. 6 ℃ ) and ( or ) local swelling ( >2. 5 cm) and ( or) local induration;9 cases was rare serious reaction ( 2. 05/100 000 doses ) with anaphylactic rash;2 cases were coupling diseases ( 0. 46/100 000 doses ). Conclusion DTaP has good immunization safety. The AEFI surveillance system runs well in Fengtai District and can provided scientific basis for vaccine safety.%目的 分析吸附无细胞百白破联合疫苗(DTaP)疑似预防接种异常反应(AEFI)的发生特征,评价DTaP预防接种的安全性和AEFI监测系统的运转情况.方法 通过疑似预防接种异常反应信息管理系统和中国免疫规划监测信息管理系统,收集北京市丰台区2008-2011年报告的AEFI个案数据,采用描述性方法进行流行病学分析.结果 北京市丰台区2008-2011年DTaP AEFI个案61例,报告发生率为13.88/10万剂次,2008、2009、2010、2011年DTaP AEFI发生率比较,差异有统计学意义(χ2=17.312,P=0.001);其中2011年AEFI发生率高于2009年,差异有统计学意义(χ2=11.018,P=0.001).不同剂次DTaP AEFI发生率比较,差异有统计学意义(χ2=95.586,P=0.000);其中第4剂次DTaP AEFI发生率高于第1、2、3剂次,差异有统计学意义(χ2值分别为38.604、39.805和35.105,P=0.000).主要报告月份为5-8月.一般反应50例(11.38/10万剂次),以重度发热(≥38.6 ℃)和(或)局部红肿(＞2.5 cm)和(或)局部硬结为主要表现;异常反应9例(2.05/10万剂次),以过敏性皮疹为主要表现;偶合症2例(0.46/10万剂次).结论 DTaP上市后具有较好的预防接种安全性,AEFI监测系统运转正常,对评价疫苗的安全性提供科学依据.
展开▼
